Thermo Fisher Scientific (Thermo) has offered to acquire Olink, a Swedish provider of proteomics analysis equipment and services for tracking down and developing biomarkers.
Through a deal worth USD 3.1 billion, Thermo has agreed to pay USD 26 for each of Olink’s shares. Olink has around USD 143 million cash in hand, alongside the company’s international operations in Boston, Tokyo, and Shanghai. The acquisition is intended to extend Thermo’s reach in protein research.
Thermo is a provider of medical equipment, analytical instruments, reagents and consumables, software, and services to tackle complex analytical challenges in research, diagnostics, and clinical laboratories. It offers solutions for cellular analysis and biology, flow cytometry, and synthetic biology. The company has a range of products, which include technologies for mass spectrometry, genetic sequencing, electron microscopy, protein, and molecular biology research.
Olink develops and markets its unique technology for protein analysis in human protein biomarker research. Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyze large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.